Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth.
PURPOSE: This clinical trial is studying how well erlotinib works in treating women
undergoing surgery for stage I, stage II, or stage III breast cancer.